Berman, Jason
IWK Grace Health Centre
An in vivo model to study gold nanoparticle aided radiotherapy using a photon beam generated from a low Z target
|
2018/2019
:
$99,500
2019/2020
:
$99,500
|
Bridle, Byram
University of Guelph
Combining oncolytic virotherapy and epigenetic modifiers to treat acute leukemias
*co-funded with CIHR-ICR
|
2018/2019
:
$100,000
2019/2020
:
$100,000
|
Cafazzo, Joseph
The Toronto Hospital (General Division) UHN
A virtual prostate cancer clinic for enhanced survivorship care
*co-funded with CIHR-ICR
|
2018/2019
:
$99,518
2019/2020
:
$99,798
|
Carreno, Sebastien
Université de Montréal
Identification of anti metastatic compounds that blocks ezrin activity
|
2018/2019
:
$100,000
2019/2020
:
$100,000
|
Diallo, Jean Simon
Ottawa Hospital Research Institute
Novel oncolytic virus vaccines exploiting dendritic cell targeting
*co-funded with CIHR-ICR
|
2018/2019
:
$100,000
2019/2020
:
$100,000
|
Diamandis, Phedias
Princess Margaret Cancer Centre UHN
Glioblastoma pharmacoproteomics: systematic proteomics based profiling and chemical interrogation of glioblastoma
*co-funded with CIHR-ICR
|
2018/2019
:
$100,000
2019/2020
:
$100,000
|
Garzia, Livia
The Research Institute of the McGill University Health Centre (RI MUHC)
Evaluation of electrical activity as a tumour suppressor in medulloblastoma
*co-funded with Brain Canada and CIBC, with the support of Health Canada
|
2018/2019
:
$99,674
2019/2020
:
$99,674
|
Gorrini, Chiara
Princess Margaret Cancer Centre UHN
Targeting aryl hydrocarbon receptor as novel vulnerability in triple negative breast cancers
*co-funded with CIHR-ICR
|
2018/2019
:
$65,000
2019/2020
:
$92,000
2020/2021
:
$43,000
|
Grandy, Scott
Dalhousie University
EXercise to prevent AnthraCycline based Cardio Toxicity (EXACT 2.0) in individuals with breast cancer
*co-funded with CIHR-ICR
|
2018/2019
:
$100,000
2019/2020
:
$100,000
|
Greer, Peter
Queen's University
Development of a biosensor for high throughput screening of novel compounds targeting ezrin for breast cancer therapy
*co-funded with CIHR-ICR
|
2018/2019
:
$100,000
2019/2020
:
$100,000
|
Ilkow, Carolina
Ottawa Hospital Research Institute
Oncolytic immunotherapy driven synthetic lethality
*co-funded with CIHR-ICR
|
2018/2019
:
$100,000
2019/2020
:
$100,000
|
Kislinger, Thomas
Princess Margaret Cancer Centre UHN
Identifying the molecular landscape of the triple negative breast cancer cell surface proteome – an avenue for new therapies
*co-funded with CIHR-ICR
|
2018/2019
:
$100,000
2019/2020
:
$100,000
|
Kubes, Paul
University of Calgary
The cavity macrophage, a friend or foe in cancer metastasis progression
*co-funded with CIHR-ICR
|
2018/2019
:
$64,270
2019/2020
:
$68,270
2020/2021
:
$68,270
|
Kuruvilla, John
Princess Margaret Cancer Centre UHN
Engineering novel 3D hydrogels to better characterize molecular cues and cellular dynamics in the lymphoma microenvironment
|
2018/2019
:
$99,320
2019/2020
:
$99,500
|
Laplante, Mathieu
l‘Institut universitaire de cardiologie et de pneumologie (IUCPQ)
Defining a new link between oncogenic growth factor signalling, mitotic defects and chromosome instability
|
2018/2019
:
$100,000
2019/2020
:
$100,000
|
Lu, Qing Bin
University of Waterloo
Development of novel combination therapy of cisplatin with a molecular promoter to treat multiple cancers
*co-funded with CIHR-ICR
|
2018/2019
:
$99,990
2019/2020
:
$100,000
|
Marra, Marco
BC Cancer Agency (Vancouver)
Dissecting tumour heterogeneity using single cell genomics, epigenomics and transcriptomics
*co-funded with CIHR-ICR
|
2018/2019
:
$99,575
2019/2020
:
$99,575
|
Moraes, Christopher
McGill University
Reconceptualizing cancer metastasis as a balance of intra tumoural mechanical forces
*co-funded with CIHR-ICR
|
2018/2019
:
$62,000
2019/2020
:
$68,000
2020/2021
:
$70,000
|
Perreault, Claude
Université de Montréal
The proteogenomic landscape of tumour specific antigens present in triple negative breast cancers
*co-funded with CIHR-ICR
|
2018/2019
:
$67,000
2019/2020
:
$67,000
2020/2021
:
$66,000
|
Prado, Carla
University of Alberta
Maximizing metastatic breast cancer patient outcomes using diet and exercise
*co-funded with CIHR-ICR
|
2018/2019
:
$72,684
2019/2020
:
$100,000
2020/2021
:
$27,316
|
Pratt, Christine
University of Ottawa
BRCA2 deficient fibroblasts in tumour promotion
*co-funded with CIHR-ICR
|
2018/2019
:
$99,610
2019/2020
:
$100,000
|
Shmulevitz, Maya
University of Alberta
Multi mechanistic oncolytic reovirus variants for clearing cancer
*co-funded with CIHR-ICR
|
2018/2019
:
$99,800
2019/2020
:
$99,800
|
Spreafico, Anna
Princess Margaret Cancer Centre UHN
Oral and intestinal microbiome profiling in intermediate risk locally advanced head and neck squamous cell carcinoma patients receiving chemoradiotherapy and immunoradiotherapy
*co-funded with CIHR-ICR
|
2018/2019
:
$59,860
2019/2020
:
$64,560
2020/2021
:
$75,000
|
Stagg, John
Université de Montréal
Immune stimulatory antibody drug conjugates for treatment of breast cancer
*co-funded with CIHR-ICR
|
2018/2019
:
$66,000
2019/2020
:
$67,000
2020/2021
:
$67,000
|
Stirling, Peter
BC Cancer Agency (Vancouver)
Promoting hypermutated genomes as a therapeutic strategy
|
2018/2019
:
$100,000
2019/2020
:
$100,000
|
Turcotte, Eric
Université de Sherbrooke
Early detection and in vivo estrogen receptor status determination of uterine and ovarian cancers using the novel PET tracer 4FMFES: a phase I/II study
|
2018/2019
:
$40,220
2019/2020
:
$76,485
2020/2021
:
$81,067
|
Yamanaka, Yojiro
McGill University
Generation of platinum resistant ovarian cancer mouse model to study susceptible cell populations in the fallopian tube epithelium
|
2018/2019
:
$100,000
2019/2020
:
$100,000
|